



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/719,188	11/21/2003	Yong-Jin Wu	CT-2749-NP	3240
23914	7590	08/29/2005	EXAMINER	
STEPHEN B. DAVIS			BERNHARDT, EMILY B	
BRISTOL-MYERS SQUIBB COMPANY			ART UNIT	
PATENT DEPARTMENT			PAPER NUMBER	
P O BOX 4000			1624	
PRINCETON, NJ 08543-4000			DATE MAILED: 08/29/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	10/719,188	WU ET AL.
	Examiner Emily Bernhardt	Art Unit 1624

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on _____.
 2a) This action is FINAL. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-8 is/are pending in the application.
 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
 5) Claim(s) 1-4 is/are allowed.
 6) Claim(s) 5 and 6 is/are rejected.
 7) Claim(s) 7 and 8 is/are objected to.
 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date <u>2/5/04</u> . | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| | 6) <input type="checkbox"/> Other: _____ |

Claim 5 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

1. Claim 5 is of indeterminate scope for the following reasons. Determining whether a given disease responds or not to “opening of the KCNQ potassium channels” involves much experimentation since a negative response from one patient does not mean the drug isn’t useful as no drug has 100% effectiveness. Thus what “success rate” determines if a particular drug is effective and how many patients (and dosage regimens) need to be tested? Further exacerbating the scope is the existence of many types of potassium channels as well as more yet to be discovered. The test for determining compliance with 35 USC 112, par. two is whether applicants have clearly defined “their” invention not what may be discovered by future research as this type of claim language clearly requires.

Claims 5 and 6 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for migraine, pain as recited in the claims, epilepsy, convulsions, does not reasonably provide enablement for remaining uses. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims. The notion that such a range of uses can be treated is not

substantiated by the current state of the art such as Gribkoff provided by the examiner. Said reference describes compounds such as retigabine, a known KCNQ 2/3 opener, having undergone more testing than herein as candidates in clinical trials for uses listed above. Note on p.742,right column, penultimate paragraph which states: "KCNQ openers may also have other therapeutic applications, although at present there are almost no data to specifically support any other indications." A few lines later it is stated: "KCNQ openers could therefore be useful in such disorders and should be tested in the appropriate models when compounds become available." Thus in the absence of animal studies and in the absence of any correlation between studies conducted *in vitro* for the diseases covered, there is no sufficient evidence to support all of the claimed uses. See Hoffman v. Klaus 9 USPQ 2d 1657;Ex parte Powers 220 USPQ 924. Note also the criteria for enablement as set out in In re Wands cited in MPEP 2164.01(a),August 2000 edition. Thus given the level of skill in this art which is low and the lack of direction (i.e. art-recognized tests) as well as working examples employing such tests, this rejection is being applied.

Claims 1-4 are allowed over the art of record as a search in the pertinent art area yielded nothing teaching or suggesting the structural makeup of piperazines claimed herein.

Claims 7 and 8 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

An "a" should be inserted after "phenyl optionally substituted with" in claim 1.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Emily Bernhardt whose telephone number is 571-272-0664.

If attempts to reach the examiner by telephone are unsuccessful, the acting supervisor for AU 1624, James O. Wilson can be reached at 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.


Emily Bernhardt
Primary Examiner
Art Unit 1624